(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 11.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Rigel Pharmaceuticals's revenue in 2026 is $282,076,000.On average, 7 Wall Street analysts forecast RIGL's revenue for 2026 to be $5,105,973,067, with the lowest RIGL revenue forecast at $4,697,567,827, and the highest RIGL revenue forecast at $5,452,845,251. On average, 7 Wall Street analysts forecast RIGL's revenue for 2027 to be $5,927,502,897, with the lowest RIGL revenue forecast at $5,261,893,112, and the highest RIGL revenue forecast at $6,811,654,863.
In 2028, RIGL is forecast to generate $7,156,167,372 in revenue, with the lowest revenue forecast at $5,744,355,836 and the highest revenue forecast at $10,705,481,178.